Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$4,683 Mln
P/E Ratio
--
P/B Ratio
10.77
Industry P/E
81.48
Debt to Equity
0
ROE
-0.18 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.35
CFO
$33.53 Mln
EBITDA
$9.96 Mln
Net Profit
$-19.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Inari Medical Inc (NARI)
| 56.65 | 0.53 | 55.83 | 36.84 | 2.68 | -- | -- |
|
BSE Sensex*
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Inari Medical Inc (NARI)
| -21.21 | 2.14 | -30.36 | 4.56 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,493.89 | 14.66 | 12.69 | |
| 71.01 | 9,784.74 | 94.85 | 2.52 | |
| 152.15 | 8,196.06 | -- | -25.23 | |
| 277.35 | 10,699.33 | 771.64 | 1.2 |
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core,... capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. As of February 19, 2025, Inari Medical, Inc. operates as a subsidiary of Stryker Corporation. Address: 6001 Oak Canyon, Irvine, CA, United States, 92618 Read more
CEO, President & Director
Mr. Andrew J. Hykes
CEO, President & Director
Mr. Andrew J. Hykes
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Inari Medical Inc (NARI) stood at $ 846 Mln as on 30-Sep-24
The share price of Inari Medical Inc (NARI) is $79.97 (NASDAQ) as of 19-Feb-2025 09:30 EDT. Inari Medical Inc (NARI) has given a return of 2.68% in the last 3 years.
Inari Medical Inc (NARI) has a market capitalisation of $ 4,683 Mln as on 19-Feb-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Inari Medical Inc (NARI) is 10.77 times as on 19-Feb-2025, a 221% premium to its peers’ median range of 3.36 times.
Since, TTM earnings of Inari Medical Inc (NARI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inari Medical Inc (NARI) and enter the required number of quantities and click on buy to purchase the shares of Inari Medical Inc (NARI).
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California. As of February 19, 2025, Inari Medical, Inc. operates as a subsidiary of Stryker Corporation. Address: 6001 Oak Canyon, Irvine, CA, United States, 92618
The CEO & director of Mr. Andrew J. Hykes. is Inari Medical Inc (NARI), and CFO & Sr. VP is Mr. Andrew J. Hykes.
There is no promoter pledging in Inari Medical Inc (NARI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,083
|
|
|
1,061
|
|
|
1,022
|
|
|
889
|
| Inari Medical Inc (NARI) | Ratios |
|---|---|
|
Return on equity(%)
|
-17.82
|
|
Operating margin(%)
|
-9.24
|
|
Net Margin(%)
|
-13.68
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inari Medical Inc (NARI) was $0 Mln.
